Cingulate (CING) Shares Outstanding (2021 - 2026)
Cingulate's (CING) quarterly Shares Outstanding (Entity) came in at $5.1 million in Q4 2025, up 231.54% YoY from $1.5 million in Q4 2024, and down 15.43% on a QoQ basis from $6.0 million in Q3 2025.
Cingulate (CING) Shares Outstanding (2021 - 2026) Analysis & Trends
Cingulate (CING) has 5 years of Shares Outstanding (Entity) data on file, last reported at $5.1 million in Q4 2025.
- Quarterly Shares Outstanding (Entity) rose 231.54% year-over-year to $5.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.1 million (up 231.54% YoY) and the FY2025 annual result came in at $5.1 million, up 231.54% from the prior year.
- Shares Outstanding (Entity) retreated to $5.1 million in Q4 2025, from $6.0 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $6.0 million in Q3 2025 to a low of $1867.0 in Q3 2021.
- A 5-year average of $1.4 million and a median of $73920.5 in 2023 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) soared 2423.89% — and 2023, when it changed 0.0%.
- Tracing CING's Shares Outstanding (Entity) over 5 years: stood at $30889.0 in 2021, then soared by 52.55% to $47121.0 in 2022, then jumped by 60.08% to $75432.0 in 2023, then soared by 1921.42% to $1.5 million in 2024, then jumped by 231.54% to $5.1 million in 2025.
- The last three Shares Outstanding (Entity) figures came in at $5.1 million (Q4 2025), $6.0 million (Q3 2025), and $4.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 133.61 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 217.35 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 445.06 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 241.70 Mn |
| 10 | Cingulate | 70.68 Mn | 70.68 Mn | - | 13.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.06 Mn |
| Dec 31, 2025 | 5.06 Mn |
| Sep 30, 2025 | 5.43 Mn |
| Jun 30, 2025 | 4.39 Mn |
| Mar 31, 2025 | 3.65 Mn |
| Dec 31, 2024 | 1.52 Mn |
| Sep 30, 2024 | 1.77 Mn |
| Jun 30, 2024 | 586,313.00 |
| Mar 31, 2024 | 412,109.00 |
| Dec 31, 2023 | 75,432.00 |
| Sep 30, 2023 | 82,358.00 |
| Jun 30, 2023 | 48,726.00 |
| Mar 31, 2023 | 47,121.00 |
| Dec 31, 2022 | 47,121.00 |
| Sep 30, 2022 | 47,121.00 |
| Jun 30, 2022 | 47,121.00 |
| Mar 31, 2022 | 47,121.00 |
| Dec 31, 2021 | 30,889.00 |
| Sep 30, 2021 | 1,867.00 |